Heteroplasmic mitochondrial DNA mutations in frontotemporal lobar degeneration.
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
01
2022
accepted:
18
04
2022
revised:
18
04
2022
pubmed:
1
5
2022
medline:
18
5
2022
entrez:
30
4
2022
Statut:
ppublish
Résumé
Frontotemporal lobar degeneration (FTLD) is a common cause of young onset dementia and is characterised by focal neuropathology. The reasons for the regional neuronal vulnerability are not known. Mitochondrial mechanisms have been implicated in the pathogenesis of FTLD, raising the possibility that frontotemporal regional mutations of mitochondrial DNA (mtDNA) are contributory causes. Here we applied dual sequencing of the entire mtDNA at high depth to identify high-fidelity single nucleotide variants (mtSNVs) and mtDNA rearrangements in post mortem brain tissue of people affected by FTLD and age-matched controls. Both mtSNVs and mtDNA rearrangements were elevated in the temporal lobe, with the greatest burden seen in FTLD. mtSNVs found in multiple brain regions also reached a higher heteroplasmy levels in the temporal lobe. The temporal lobe of people with FTLD had a higher burden of ribosomal gene variants predicted to affect intra-mitochondrial protein synthesis, and a higher proportion of missense variants in genes coding for respiratory chain subunits. In conclusion, heteroplasmic mtDNA variants predicted to affect oxidative phosphorylation are enriched in FTLD temporal lobe, and thus may contribute to the regional vulnerability in pathogenesis.
Identifiants
pubmed: 35488929
doi: 10.1007/s00401-022-02423-6
pii: 10.1007/s00401-022-02423-6
pmc: PMC9107417
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-695Subventions
Organisme : Medical Research Council
ID : MC_UU_00005/12
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1501/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S035699/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00015/9
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00028/7
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212219/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13047
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008886/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
EMBO Mol Med. 2015 Dec 14;8(1):58-72
pubmed: 26666268
PLoS Genet. 2020 Dec 14;16(12):e1009242
pubmed: 33315859
Science. 2018 Feb 2;359(6375):555-559
pubmed: 29217584
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Nat Commun. 2021 Sep 2;12(1):5241
pubmed: 34475388
CNS Drugs. 2010 May;24(5):375-98
pubmed: 20369906
Bioinformatics. 2014 Nov 1;30(21):3115-7
pubmed: 25028726
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
J Neurochem. 2016 Aug;138 Suppl 1:54-70
pubmed: 27306735
Science. 2015 Oct 2;350(6256):94-98
pubmed: 26430121
Nat Commun. 2019 Mar 5;10(1):1047
pubmed: 30837471
Acta Neuropathol Commun. 2017 Feb 2;5(1):13
pubmed: 28153046
Neurobiol Aging. 2019 Jun;78:98-110
pubmed: 30925302
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4696-4705
pubmed: 30770445
Elife. 2014 Oct 01;3:
pubmed: 25271376
Nat Commun. 2018 Oct 15;9(1):4257
pubmed: 30323172
Nat Rev Genet. 2021 Feb;22(2):106-118
pubmed: 32989265
Curr Opin Neurol. 2011 Dec;24(6):542-9
pubmed: 21986680